Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.78 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975151 | 0.88 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL10297353 | 0.88 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL16208179 | 0.88 | HSD11B1 (0.60) | HSD11B1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL974888 | 0.86 | HSD11B1 (0.84) | HSD11B1HSD11B2CYP3A4CYP2C19 | |
| SCHEMBL975230 | 0.85 | HSD11B1 (0.80) | HSD11B1HSD11B2 | |
| SCHEMBL10297236 | 0.85 | HSD11B1 (0.80) | HSD11B1HSD11B2 | |
| SCHEMBL973781 | 0.85 | HSD11B1 (0.79) | HSD11B1HSD11B2 | |
| SCHEMBL973399 | 0.85 | HSD11B1 (0.93) | HSD11B1HSD11B2 | |
| SCHEMBL972582 | 0.84 | HSD11B1 (0.78) | HSD11B1HSD11B2CYP3A4CYP2C19 | |
| SCHEMBL973102 | 0.83 | HSD11B1 (0.79) | HSD11B1HSD11B2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | BHMT, UGDH, NNMT | HSD11B1 4293/4885HSD11B2 4431/4885USP2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.